NanoBio Corporation announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine.
The details can be read here.
No comments:
Post a Comment